Clinical Trial Update: Efficacy and Safety of Everolimus+EC-MPS After Early CNI Elimination vs EC-MPS +Tacrolimus in Renal Transplant Recipients [Phase 4]

View source ↗

Summary

A Phase 4 trial comparing everolimus with enteric-coated mycophenolate sodium after early elimination of calcineurin inhibitors to enteric-coated mycophenolate …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Failure

Drugs mentioned

• Afinitor (everolimus)
• MYFORTIC (MYCOPHENOLIC ACID)
• Prograf (Tacrolimus)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Renal Failure | Phase 4 | Status: COMPLETED | Results posted: 2014-08-15